Skip to main content
. 2020 Jun;9(3):617–628. doi: 10.21037/tlcr-20-231

Figure 1.

Figure 1

Group score class for patients with (A) progressive disease (PR), (B) stable disease (SD), (C) progressive disease (PD) and (D) not valuable (NV) response due to adverse effects or clinical deterioration. Dot size is proportional with the number of patients in the respective score classes.